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Graphical Abstract
Highlights 
- Male androgen biosynthesis shows a significant peak at week 7 during minipuberty  
- Androgens in minipuberty are (at least in part) produced through the backdoor pathway 
- Steroid enzyme activities in the first year of life are all age-, some sex-specific 
- Steroid enzyme ratios obtained from urine GC-MS are comparable between laboratories 
*Highlights (for review)
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
1 
 
Androgen biosynthesis during minipuberty favors the backdoor pathway over the classic pathway: 1 
insights into enzyme activities and steroid fluxes in healthy infants during the first year of life from 2 
the urinary steroid metabolome 3 
Abbreviated title: Minipuberty uses the backdoor androgen pathway 4 
 5 
Nasser A. Dhayat
a
, Bernhard Dick
a
, Brigitte M. Frey
a
, Claudia H. d`Uscio
a
, Bruno Vogt
a
, Christa E. 6 
Flück
b
 7 
 8 
a
Department of Nephrology, Hypertension and Clinical Pharmacology, Inselspital, Bern University 9 
Hospital, University of Bern, Freiburgstrasse 15, 3010 Bern, Switzerland; nasser.dhayat@insel.ch; 10 
claudia.d'uscio@insel.ch; bruno.vogt@insel.ch; bernhard.dick@insel.ch; brigitte.frey@dkf.unibe.ch 11 
b
Department of Pediatrics (Pediatric Endocrinology and Diabetology, University Children’s Hospital) and 12 
Department of Clinical Research, Inselspital, Bern University Hospital, University of Bern, 13 
Freiburgstrasse 15, 3010 Switzerland; christa.flueck@dkf.unibe.ch 14 
 15 
Keywords: newborn infants, GC-MS, urinary steroid profile, urinary steroid metabolome, minipuberty, 16 
androgens, steroid enzyme activity, development 17 
 18 
Corresponding author and person to whom reprint requests should be addressed: 19 
Christa Flück, M.D. 20 
University Children’s Hospital Bern 21 
Freiburgstrasse 15 / C845 22 
3010 Bern 23 
Switzerland 24 
Phone: +41 31 632 04 99 25 
Email: christa.flueck@dkf.unibe.ch 26 
 27 
*Manuscript
Click here to view linked References
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
2 
 
Word count: abstract 250, text body 3620 28 
Figures/Tables: Tables 3, Figures 2 29 
Suppl Material: Figure 1 (multiple) 30 
References: 34 31 
 32 
Supporting grant: SNSF 320030-146127 to CEF 33 
 34 
Author disclosure summary: The authors have nothing to disclose.  35 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
3 
 
Abstract 36 
The steroid profile changes dramatically from prenatal to postnatal life. Recently, a novel backdoor 37 
pathway for androgen biosynthesis has been discovered. However, its role remains elusive. Therefore, we 38 
investigated androgen production from birth to one year of life with a focus on minipuberty and on 39 
production of androgens through the backdoor pathway. Additionally, we assessed the development of the 40 
specific steroid enzyme activities in early life. To do so, we collected urine specimens from diapers in 43 41 
healthy newborns (22 females) at 13 time points from birth to one year of age in an ambulatory setting, 42 
and performed in house GC/MS steroid profiling for 67 steroid metabolites. Data were analyzed for 43 
androgen production through the classic and backdoor pathway and calculations of diagnostic ratios for 44 
steroid enzyme activities were performed. Analysis revealed that during minipuberty androgen production 45 
is much higher in boys than in girls (e.g. androsterone (An)), originates largely from the testis (An
boys
-46 
An
girls
), and uses predominantly the alternative backdoor pathway (An/Et; Δ5<Δ4 lyase activity). 47 
Modelling of steroid enzyme activities showed age-related effects for 21-, 11-, 17-hydroxylase and P450 48 
oxidoreductase activities as well as 3β-hydroxysteroid dehydrogenase, 11β-hydroxylase type 1/2 and 5α-49 
reductase activities. Sex-related characteristics were found for 21-hydroxylase and 5α-reductase activities. 50 
Overall, our study shows that androgen biosynthesis during minipuberty favors the backdoor pathway 51 
over the classic pathway. Calculations of specific diagnostic ratios for enzyme activities seem to allow the 52 
diagnosis of specific steroid disorders from the urinary steroid metabolome.  53 
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1. Introduction 54 
During the first year of life the steroid metabolome changes remarkably, mainly due to three 55 
developmental events (1). First, the fetal-placental-maternal unit, which is a steroid forming and 56 
metabolizing unit during pregnancy, is disrupted at birth. Second, the fetal adrenal, which produces 57 
predominantly dehydroepiandrosterone (DHEA) involutes in the first 3-6 months; and third, steroid 58 
organs develop. Within months postnatally the adult adrenal cortex is ready to produce mineralocorticoids 59 
and glucocorticoids, while the production of adrenal C19 steroids starts very slowly after birth and 60 
becomes clinically apparent only after 6-8 years of age at adrenarche (2). Similarly, androgen production 61 
in the testis, which is highly active in mid-gestation, decreases after birth, but reveals a postnatal surge 62 
during the so-called minipuberty. By contrast, the human ovary is thought to be steroidogenically 63 
quiescent during pregnancy and prepubertal years (3). 64 
Minipuberty, characterized by a transient surge of testosterone and its precursor androstenedione due to a 65 
transient activation of the hypothalamic-pituitary-gonadal axis, has been described in male neonates aged 66 
1-3 months many years ago (4), but its role remains unclear. Minipuberty may be important for early and 67 
late postnatal sexual differentiation in males. This differentiation includes, first, postnatal phallic growth 68 
(5) and an increase in testicular volume due to an increase in seminiferous tubules (6), Sertoli cell 69 
numbers and the number of germ cells (7,8) in preparation for future spermatogenesis (9). Second, during 70 
minipuberty masculinization of the brain is modulated. This is illustrated by studies showing an 71 
association between testosterone levels at 3-4 months of age and emotional regulation in early infancy 72 
(10), a relation between testosterone levels in the first six months of life with neurobehavioral sexual 73 
differentiation at 14 months (11), and an effect of testosterone on language function, hemispheric 74 
organization and lateralization of the brain as early as 4 weeks after birth (12). Third, minipuberty seems 75 
to correlate with somatic development, as testosterone and luteinizing hormone (LH) levels at 8 weeks of 76 
life correlate with body weight and body mass index (BMI) at six years of age (13). By contrast, the 77 
hormonal pattern during the time of minipuberty is highly variable and less clear in girls (14). Thus, 78 
further characterization of the event minipuberty is needed. 79 
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Recently, an alternative backdoor pathway for dihydrotestosterone (DHT) synthesis has been described, 80 
first in marsupials (15), then in humans (16). It has been suggested that this pathway is important for male 81 
sexual differentiation in utero and that it is functional in the fetal testis. We have shown that the genes of 82 
this backdoor pathway are differently expressed in the fetal compared to the adult testis (17), likely 83 
determining the flow through the classic and the alternative androgen biosynthetic pathways. The role of 84 
the backdoor pathway and its relationship to the classic pathway in minipuberty is unknown, but can be 85 
investigated by studying the profile of androgen metabolites excreted in the urine during the first 3-6 86 
months of life. 87 
Inborn errors of steroid biosynthesis and sex development are rare disorders. Steroid measurements are 88 
first line investigations for diagnosing specific disorders before performing genetic analysis (1,18). For 89 
many steroid biosynthetic defects caused by monogenic disorders, the steroid profile reveals characteristic 90 
changes, which may be recognized as a diagnostic pattern or as alterations of substrate to product 91 
conversion ratios correlating to specific enzyme activities and thus genes. For instance, the urine steroid 92 
profile of P450 oxidoreductase deficiency shows a pattern of increased 17-hydroxyprogesterone and 21-93 
deoxycortisol metabolites (due to 21-hydroxylase deficiency), increased corticosterone metabolites (due 94 
to 17-hydroxylase deficiency), and decreased excretion of androgen metabolites (19,20). However, 95 
pathologic steroid patterns and ratios as surrogate markers of enzyme activities may only be recognized 96 
with the knowledge of normal physiology. As genetic disorders of steroidogenesis mostly manifest in the 97 
first year of life, knowledge on normal changes of the steroid profile, the steroid patterns and the substrate 98 
to product ratios during this time period are essential to use urinary steroid profiling as a diagnostic tool. 99 
Therefore, the purpose of this study was twofold. First, to describe the characteristics of the urinary 100 
androgen metabolome during the time of minipuberty. Specifically, we aimed to investigate the possible 101 
role of the backdoor androgen biosynthesis pathway during minipuberty. Second, we analyzed the 102 
physiologic development of enzyme activities of steroidogenesis by calculating conversion ratios from 103 
urine metabolites during the first year of life. In a recent project, we have measured 67 steroids in the spot 104 
urine of 43 healthy, term-born neonates at 13 time points during the first year of life by gas GC-MS (21). 105 
This big, normative dataset was now analyzed to solve our specific questions. 106 
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 107 
2. Materials and Methods 108 
2.1. Study population and urine collection procedures 109 
The study was approved by the medical ethics committee of the Kanton Bern, Switzerland. Parents gave 110 
written informed consent. In brief, 43 healthy Caucasian girls and boys born at term with normal weight 111 
and length were recruited. Spot urines were collected at weeks 1, 3, 5, 7, 9, 11, 13, 17, 21, 25, 33, 41 and 112 
49 of life. Details are described in (21). 113 
 114 
2.2. Measurement of urinary steroid metabolites by GC-MS and quality assessment 115 
Quantitative analysis of 67 urinary steroid hormone metabolites was performed by an in-house GC-MS 116 
method (21), adapted from reported methods (22). In brief, after medroxyprogesterone was added as a 117 
recovery standard, the urine sample was extracted on a Sep-Pak C18 column, then hydrolyzed with 118 
sulfatase and β-glucuronidase/arylsulfatase and free steroids were again extracted on a Sep-Pak C18 119 
cartridge. The two standards Stigmasterol and 3β5β-TH-aldosterone were added to the extract, then 120 
methoxyamine HCl 2% in pyridine was added and the sample was heated at 60°C for one hour. After 121 
evaporation of the solvent, trimethylsilylimidazole (TMSI) was added and the extracts were heated at 122 
100°C for 16 hours and then purified by gel filtration on Lipidex 5000 columns to remove the excess of 123 
derivatization reagent. The derivatized samples were analyzed by mass spectrometric analyses on a gas 124 
chromatograph 7890A from Agilent Technologies (La Jolla, California, USA) coupled to a mass selective 125 
detector Hewlett-Packard 5975C providing selected ion monitoring (SIM). For all steroids the signal-to-126 
noise-ratio was ≥3. Intra- and inter-assay variations are reported in Appendix Table B of (21). The 127 
QuantiChrom Creatinine Assay (DICT-500; BioAssay Systems, Hayward, CA, USA) was used to 128 
measure urinary creatinine by quantitative colorimetry. Measured steroids were standardized by urinary 129 
creatinine concentration and expressed in µg/mmol creatinine. Minimal urine volume required for steroid 130 
analysis was 200 μl, standard volume was 1.5 ml; for creatinine measurement 5 μl urine was used. The 131 
reproducibility of our in-house GC-MS method is continuously monitored by an internal quality control. 132 
In addition, our laboratory participates in regular external quality controls organized by the University 133 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
7 
 
College London Hospitals (London, United Kingdom) and by the Foundation for Quality Medical 134 
Laboratory Diagnostics skml (Stichting Kwaliteitsbewaking Medische Laboratoriumdiagnostiek, 135 
Nijmegen, The Netherlands). 136 
 137 
2.3. Data analysis and statistics 138 
All calculations and statistical analyses were conducted using the R software, version 3.2.2 (23). The 139 
urinary steroid metabolites µg/mmol creatinine were converted to μmol/mol creatinine using the molar 140 
mass of each steroid compound (see Table 1 of Ref. (21)). 141 
To explore the role of the backdoor pathway for androgen biosynthesis, age- and sex-related changes of 142 
androsterone and of the steroid ratios of Table 1 were modeled by multivariable linear quantile mixed 143 
regression taking subject as random effect into account (24). Sex and age were included as fixed effects. 144 
We considered five age-effects: constant (corresponding to no age effect), linear and natural quadratic, 145 
natural cubic and natural quartic splines. Since we considered the presence of a sex effect, we fitted a total 146 
of 10 possible models for androsterone and each steroid ratio and selected that model minimizing the 147 
Akaike information criterion (AIC). Quantile regression makes no distributional assumption, thus, no 148 
transformation of the steroid ratio values were necessary. Continuous conditional 25
th
, 50
th
 and 75
th
 149 
quantiles were plotted by combined use of quantile regression and natural splines according to the 150 
selected model (Figure 1) (25). As the adrenals and the testes are active in producing androgens during 151 
minipuberty, while the ovaries seem rather quiescent, the contribution of the testes to androgen 152 
production was calculated by subtracting the median values in girls from the median values in boys and 153 
continuous conditional 25
th
, 50
th
 and 75
th
 quantiles were plotted (Figure 1). The median values of 154 
androsterone and of the steroid ratio androsterone/etiocholanolone in male infants were compared to 155 
female infants by Mann-Whitney U test for each time point. 156 
Urinary steroid metabolites expressed in μmol/mol creatinine were used to calculate the urinary steroid 157 
metabolite ratios or fluxes listed in Table 2. Sex and age specific dependencies were modeled by 158 
multivariable linear quantile mixed regression and were visualized by quantile regression and natural 159 
splines as described before (Figure 2 and Supplement Figures). The maximum value and the 97.5
th
 160 
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quantile were determined for each ratio at each week of life and, in case of a sex difference derived from 161 
the quantile regression mixed model, the values were calculated separately for boys and girls (Table 3). 162 
 163 
3. Results 164 
3.1. Androgen production through the backdoor pathway predominates during minipuberty 165 
To characterize the androgen biosynthesis from birth to one year of life, we analyzed the urinary steroid 166 
metabolome of 43 infants for sex- and age-dependent androsterone excretion (15,26-28). In a 167 
multivariable linear quantile mixed model, we found both a sex- and age-dependency. The continuous 168 
conditional 25
th
, 50
th
 and 75
th
 quantiles were plotted using quantile regression and natural splines (Figure 169 
1A). Urinary excretion of androsterone was similar between boys and girls at week 1, but increased 170 
significantly during minipuberty only in boys to a maximum at week 7, before decreasing to a baseline 171 
level as found in girls at week 17. Accordingly, higher median values of androsterone [μmol/mol 172 
creatinine] in male infants compared to female infants by Mann-Whitney U test were found at week 3 173 
(59.8 vs. 37.3; p=0.011), week 5 (59.9 vs. 48.6; p=0.11), week 7 (85.4 vs. 35.6; p=0.0083), week 9 (57.4 174 
vs. 33.5; p=0.012), week 11 (49.3 vs. 21.9; p=0.029) and week 13 (45.2 vs. 30.0; p=0.13). To assess the 175 
amount of androgen production that arises from the backdoor pathway in comparison to the classic 176 
pathway, we calculated the androsterone/eticholanolone ratio, which represents the backdoor pathway 177 
androgen synthesis after the 17,20-lyase reaction (27-29). This ratio showed a sex- and age-dependency. 178 
The quantile regression/natural splines plot showed no sex difference for the ratio at week 1, but an 179 
increase for boys until week 7 and a decline thereafter (Figure 1B). Higher median values in males were 180 
found at week 5 (6.1 vs. 2.8; p=0.19), week 7 (10.1 vs. 4.6; p=0.014), week 9 (7.7 vs. 4.3; p=0.18), week 181 
11 (4.5 vs. 3.2; p=0.16) and week 13 (5.6 vs. 3.5; p=0.12). 182 
Generally, both the gonads and the adrenals contribute towards the urinary metabolome. However, the 183 
prepubertal ovary is inactive. Thus, subtracting the androgen production found in females from the 184 
production in males (in the first year of life), will subtract the adrenal contribution and reveal the 185 
androgen production by the testis only. This calculation showed a significant increase of androsterone 186 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
9 
 
production (Figure 1 C) and an increased ratio of androgen production through the backdoor pathway 187 
compared to the classic pathway during the time of minipuberty for the testis (Figure 1D).  188 
We also performed calculations for the 17,20 lyase activity, which is essential for any androgen 189 
production, but may follow the so-called Δ5- or Δ4-steroid pathway. The Δ5-pathway leads from 190 
pregnenolone to 17-hydroxy-pregnenolone to DHEA and thus directly to the classic androgen 191 
biosynthetic path; the Δ4-pathway leads to 17-hydroxyprogesterone as precursor, which is hardly 192 
converted to androstenedione (30), but may readily feed into the backdoor path. Our analysis revealed a 193 
steep decrease from a high level for the Δ5-pathway lyase activity after birth to week 11 (Figure 1E) and 194 
a steep increase from a very low level for the Δ4-pathway lyase activity (Figure 1F). While the Δ5-195 
activity remained relatively low after week 11, the Δ4-activity showed a mild, continued increase beyond 196 
week 11, but at a low level (similar to Δ5-activity). 197 
 198 
3.2. Most steroid enzyme activities are age- but not sex-specific during the first year of life 199 
Forty-one formula for the calculation of substrate to product conversion ratios representing specific 200 
steroid enzyme activities were created based on published literature (Table 2). The respective calculations 201 
using our dataset are shown in Table 3. The maximum value and the 97.5
th
 quantile for each ratio at 13 202 
time-points stratified by sex in case of sex difference are presented. For the vast majority of ratios the 203 
maximum value and the 97.5
th
 quantile lied very close to each other, but in several cases the maximum 204 
value also exceeded the twofold or threefold of the 97.5
th
 quantile. In a mixed effect quantile regression 205 
model, age-related characteristics were generally found for all analyzed enzyme activities. Only for 21-206 
hydroxylase (21-OHase) and 3β-hydroxysteroid-dehydrogenase (3β-HSD) activities, some calculations 207 
did not reveal this effect (Table 3). In contrast, a sex-related effect was only found for 21-OHase and 5α-208 
reductase activities. Only 2/9 calculations for 3β-HSD and 1/5 calculations for 17α-hydroxylase (17-209 
OHase) activities revealed a sex effect, while no such effect was found for 11-hydroxylase, P450 210 
oxidoreductase and 11β-hydroxysteroid-dehydrogenase type 1/2 (Table 3). 211 
In addition to the maximum value and the 97,5
th
 quantile, the continuous conditional 25
th
, 50
th
 and 75
th
 212 
quantiles of all 41 steroid ratios were visualized according to the selected model (Supplemental Material 213 
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Figure 1). Figure 2 shows the developmental pattern of four ratios from birth to 12 months. Figure 2A 214 
represents the best ratio to discriminate 21-OHase deficiency from normal 21-OHase activity reported by 215 
Kamrath et al. using 6OH-THE as the denominator (31). The ratio shows an association with sex and age. 216 
Starting at a similar level after birth, the relative 21-OHase activity decreased faster in girls in the first 217 
three months of life (corresponding to an increase in the ratio), while the decrease in boys occurred later. 218 
Figure 2B shows the pattern for the 3β-HSD activity in the first year of life using again 6OH-THE as the 219 
denominator of the ratio. For this ratio an association with age, but not with sex was found. After birth, 220 
the relative 3β-HSD activity rapidly declined to 50% by week seven, then increased to a relative 221 
maximum by week eleven, and then declined again. 222 
A representative pattern for the 17-OHase activity is shown in Figure 2C. An age, but no sex effect was 223 
found for this ratio. The 17-OHase activity seemed to increase slightly after birth till week seven and 224 
decreased thereafter continuously. 225 
Finally, a representative ratio for the 5α-reductase activity is given in Figure 2D. Its ratio showed an 226 
association with sex and age. Relative 5α-reductase activity increased massively after birth in both sexes 227 
and was found highest between week seven and 17. Overall, 5α-reductase activity was higher in boys 228 
compared to girls, which corresponds to a lower ratio. 229 
 230 
4. Discussion 231 
The backdoor pathway for androgen biosynthesis is relatively novel and its exact role unclear (1). In 232 
previous work, we have shown through studies of human mutations in genes involved in the backdoor 233 
pathway that it is needed for normal fetal male sexual development, and that the gene expression profile 234 
of backdoor pathway genes changes from fetal to adult life in the human testis (16,17). Similarly, the role 235 
of the event minipuberty, which occurs predominantly in males around postnatal days 30-100, remains 236 
unclear (3). Therefore, we aimed to model the androgen production from birth to one year of life and 237 
calculated the contribution of the backdoor path to overall androgen biosynthesis using our steroid 238 
metabolome databank (21). Interestingly, we were able to model the event minipuberty by tracking the 239 
specific androgen metabolites in the urine. As expected, the rise in androgen production during 240 
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minipuberty is much more significant in boys than in girls, and the androgen source seems confined to the 241 
testis. As novel information, we found that androgen production during minipuberty seems to occur rather 242 
through the backdoor pathway than through the classic pathway. This is supported by calculations for the 243 
precursor/product ratio androsterone/etiocholanolone (An/Et) and by flux calculations looking at 17,20 244 
lyase activity, which is essential for any androgen production. Higher An/Et ratio during minipuberty 245 
suggests enhanced backdoor pathway activity. This An/Et ratio is also reported as a formula for assessing 246 
5α-reductase activity in the first year of life and showed an identical pattern as seen in our cohort (32). 247 
While lyse activity in the Δ5-path rather leads to the classic androgen biosynthesis, the Δ4-path produces 248 
17-hydroxyprogesterone, which rather feeds into the backdoor path. In our cohort, lyase activity in the 249 
Δ5-path was extremely high at birth and dropped massively after birth to 10 weeks of age. This likely 250 
reflects the involution of the fetal adrenal gland, which produces exclusively DHEA over the Δ5-path, 251 
while postnatally the adult adrenal cortex in the first year of life does not produce androgens. By contrast, 252 
a significant rise in lyase activity in the Δ4-path within the first 10 weeks postnatally in our cohort may 253 
reflect higher androgen biosynthesis through the backdoor pathway in the testis during minipuberty. 254 
Overall, our data suggest that during the first three months of life the human testis favors the backdoor 255 
over the classic pathway for producing androgens. As androgen production during minipuberty is needed 256 
for normal postnatal male sexual development (3), the backdoor pathway is not only crucial for prenatal 257 
male sexual development (16,17), but also plays an important role after birth. 258 
 259 
The second aim of this study was to model the development of steroid enzyme activities implicated in 260 
human disorders of steroidogenesis (e.g. congenital adrenal hyperplasia (CAH)) from data collected in 261 
our urinary steroid databank (21). The purpose of the calculation of a specific precursor to product ratio 262 
(as surrogate marker for an enzyme activity) is to obtain reliable cut-offs for diagnosing steroid disorders 263 
from the urinary steroid profile. An ideal diagnostic ratio should be able to discriminate a deficient 264 
enzyme activity from a normal one. As the calculated steroid metabolite ratios usually show a wide 265 
variability especially in the upper range, which represents a low enzyme activity, it has been suggested in 266 
the literature to describe the diagnostic ratios by the maximum values and the 97.5
th
 quantiles found in 267 
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controls (31). We did that accordingly and summarized our data of diagnostic ratios in Table 3. By 268 
contrast, to illustrate the development of the enzyme activities during the first year of life, we assessed the 269 
highly skewed distributed data by the median and IQR (Supplemental Figures). In principal, all ratios 270 
assessing 21-OHase, 3β-HSD, 11-OHase, 17-OHase, POR, 11-HSD1/2 and 5α-reductase activities are 271 
age-dependent in the first year of life. In addition, 21-OHase and 5α-reductase seem to be sex-dependent. 272 
For some ratios, we were able to find normative data for comparison in the literature (29,31-33). In 273 
general, calculated ratios for steroid enzyme activities of our study compared very well with other studies, 274 
indicating that comparisons of data between laboratories and methods are possible when using ratios. 275 
However, only for ratios describing the 21-OHase activity, we found two studies, in which data of 276 
controls were assessed in comparison with a group of affected CAH patients (31,33). In the bigger and 277 
more recent study comparing 21-OHase deficient patients (n=95) to controls (n=261), it has been shown 278 
that only steroid ratios with the 21-deoxycortisol metabolite pregnanetriolone (PTO) as the numerator in 279 
combination with urinary glucocorticoid metabolites as the denominator where able to discriminate 21-280 
OHase deficiency from controls (31). The best diagnostic ratio was PTO to 6α-OH-tetrahydrocortisone, 281 
which was >8.5 fold higher in 21-OHase deficiency. Compared to this excellent study, which clearly sets 282 
the standard for future use of diagnostic ratios, our data are well in line with the control group. Thus, 283 
using our data, we should be able to diagnose 21-OHase deficiency from the urinary steroid profile 284 
unambiguously. Furthermore, it appears that once established, diagnostic ratios can be applied between 285 
labs and methods for the analysis of the urinary steroid profile with respect to steroid enzyme 286 
deficiencies. 287 
Unfortunately, there are no larger studies available assessing the specificity and the predictive value of 288 
diagnostic ratios for 3β-HSD, 11-OHase, 17-OHase, POR and 11-HSD1/2 deficiencies. Although many 289 
reported ratios have been labeled as being diagnostic in single patients, their discriminating value awaits 290 
testing in larger groups. This difficult task might only be solved through collaborations between 291 
laboratories assessing urinary steroid profiles, because those steroid disorders are very, very rare. In 292 
addition, diagnostic urine samples are only available at the very beginning, as most patients require 293 
(immediate) steroid replacement therapy, which will mask the diagnostic pattern of the disorder in the 294 
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urinary steroid profile. Also, urinary steroid profiling by GC-MS is not widely established as a diagnostic 295 
method. Thus, in many patients with a genetic steroid disorder, no diagnostic urine sample and steroid 296 
profile has been collected before treatment. Taking a patient off treatment for diagnostic purpose bears a 297 
certain risk and, therefore, mostly leads to a direct genetic work-up in undiagnosed patients under steroid 298 
therapy. Aware of those difficulties, we are collecting GC-MS generated urine steroid profiles of rare 299 
patients with steroid disorders in a local databank and recommend colleagues to do the same. 300 
Another limitation of studies in the field is that different formula for the estimation of enzyme activities 301 
are used according to individually measured urinary steroid metabolites. Although those formula may all 302 
characterize the same enzyme activity, they cannot be directly compared when not using identical 303 
precursors and products for the calculations. In our study, we encountered this problem for several ratios, 304 
which led to the creation of adapted ratios. In the future, it may be therefore recommended to define the 305 
diagnostic ratios precisely. This will require some standardization in GC-MS urinary steroid profiling, but 306 
will have the advantage that diagnostic ratios will be comparable between laboratories. 307 
 308 
In conclusion, studies of the urinary steroid metabolome are valuable for solving specific questions on 309 
easily available biomaterial. We show that androgen biosynthesis through the backdoor pathway 310 
predominates during minipuberty. Additionally, we provide longitudinal normative data for diagnostic 311 
ratios for steroid enzyme activities. 312 
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Figure Legends 418 
 419 
Figure 1 420 
Assessment of androgen production through the alternative backdoor pathway. All figures were created 421 
by the combined use of the quantile regression method and natural splines. The solid lines represent the 422 
50
th
 and the dashed lines the 25
th
 and 75
th
 quantiles. Figure A shows overall androgen production over the 423 
first 12 months of life using androsterone as a surrogate metabolite. Figure B shows the flux through the 424 
backdoor pathway using the established ratio androsterone/etiocholanolone (29). In Figure A and B black 425 
lines are used for boys and grey lines for girls. In Figure C and D the contribution to androgen production 426 
by testes only is depicted. In Figure E and F the 17,20 lyase activities of the Δ5- and the Δ4-steroid 427 
pathway are shown; age effects were found, but no sex differences. The ID number of the steroid 428 
compound /steroid ratio from Table 1 is indicated in square brackets. 429 
 430 
Figure 2 431 
Assessment of sex- and age-specific dependencies of urinary steroid metabolite ratios corresponding to 432 
specific enzymes of steroidogenesis. All figures were created by the combined use of the quantile 433 
regression method and natural splines. The solid lines represent the 50
th
 and the dashed lines the 25
th
 and 434 
75
th
 quantiles. Black lines are used for boys and grey lines for girls. A, sex- and age-specific pattern for a 435 
specific ratio representing the 21-hydroxylase. B, age-dependent pattern for the 3β-hydroxysteroid 436 
dehydrogenase. C, age-dependent pattern for the 17α-hydroxylase. D, age- and sex-dependent pattern for 437 
the 5α-reductase during the first 12 months of life. The ID number of the steroid ratio from Table 2 is 438 
indicated in square brackets. 439 
Figure1
Click here to download high resolution image
Figure2
Click here to download high resolution image
Table 1. Urinary steroid metabolites and ratios for the evaluation of the flux through the alternative backdoor pathway 
for androgen production. Established formula and calculations. 
ID Metabolites/Ratios Abbreviation Reference 
  ANDROGEN GENERATED FROM THE CLASSIC AND THE ALTERNATIVE BACKDOOR PATHWAY 
 1 androsterone AT Auchus et al. 2004 (15)  
  ALTERNATIVE BACKDOOR PATHWAY AFTER THE 17,20 LYASE VS. CLASSIC PATHWAY ACTIVITY 
 2 androsterone/etiocholanolone AT/ET Kamrath et al. 2012 (29) 
  CYP17A1 (17,20 LYASE) ACTIVITY FOR THE Δ
5
-STEROID PATHWAY 
 3 (dehydroepiandrosterone+16α-OH-dehydroepiandrosterone+ 
  androstenediol)/pregnenetriol 
(DHEA+16OH-DHEA+ 
  Δ5-diol)/5PT 
Homma et al. 2006 (28) 
  CYP17A1 (17,20 LYASE) ACTIVITY FOR THE Δ
4
-STEROID PATHWAY 
 4 11β-OH-androsterone/pregnanetriol 11β-OH-AT/PT Homma et al. 2006 (28) 
 
Table1
Table 2. Formula to calculate for steroid conversion ratios representing relative steroid enzyme activities involved in genetic 
steroid disorders. 
 
 
 
ID Disorders and pathways and their diagnostic ratios Ratio abbreviation Reference
a
 
21-HYDROXYLASE DEFICIENCY (21OHD) 
  5 pregnanetriolone/TH-cortisone PTO/THE Kamrath et al. 2016 (31) 
  6 pregnanetriolone/6α-OH-TH-cortisone PTO/6OH-THE Kamrath et al. 2016 (31) 
  7 pregnanetriolone/ 
  (TH-cortisone+6α-OH-TH-cortisone) 
PTO/(THE+6OH-THE) Kamrath et al. 2016 (31) 
  8 pregnanetriolone/(TH-cortisone+ 
  6α-OH-TH-cortisone+6α-OH-β-cortolone) 
PTO/(THE+6OH-THE+6OH-β-Cl) Kamrath et al. 2016 (31) 
3β-HSD DEFICIENCY (3HSDD) 
  9 pregnenetriol/TH-cortisone 5PT/THE Caulfield et al. 2002 (33) 
Kamrath et al. 2016 (31) 
10 pregnenetriol/6α-OH-TH-cortisone 5PT/6OH-THE Caulfield et al. 2002 (33) 
Kamrath et al. 2016 (31) 
11 pregnenetriol/(TH-cortisone+6α-OH-TH-cortisone) 5PT/(THE+6OH-THE) Caulfield et al. 2002 (33) 
Kamrath et al. 2016 (31) 
12 pregnenetriol/(TH-cortisone+6α-OH-TH-cortisone+ 
  6α-OH-β-cortolone) 
5PT/(THE+6OH-THE+6OH-β-Cl) Caulfield et al. 2002 (33) 
Kamrath et al. 2016 (31) 
13 dehydroepiandrosterone/TH-cortisone DHEA/THE Krone et al. 2010 (34) 
Kamrath et al. 2016 (31) 
14 dehydroepiandrosterone/6α-OH-TH-cortisone DHEA/6OH-THE Krone et al. 2010 (34) 
Kamrath et al. 2016 (31) 
15 dehydroepiandrosterone/(TH-cortisone+ 
  6α-OH-TH-cortisone) 
DHEA/(THE+6OH-THE) Krone et al. 2010 (34) 
Kamrath et al. 2016 (31) 
16 dehydroepiandrosterone/(TH-cortisone+ 
  6α-OH-TH-cortisone+6α-OH-β-cortolone) 
DHEA/(THE+ 
  6OH-THE+6OH-β-Cl) 
Krone et al. 2010 (34) 
Kamrath et al. 2016 (31) 
RATIO TO DISTINGUISH 3β-HSD DEFICIENCY FROM 21-HYDROXYLASE DEFICIENCY 
17 pregnenetriol/pregnanetriolone 5PT/PTO Caulfield et al. 2002 (33) 
11β-HYDROXYLASE DEFICIENCY (11OHD) 
18 TH-11-deoxycortisol/TH-cortisone THS/THE Caulfield et al. 2002 (33) 
Kamrath et al. 2016 (31) 
19 TH-11-deoxycortisol/6α-OH-TH-cortisone THS/6OH-THE Caulfield et al. 2002 (33) 
Kamrath et al. 2016 (31) 
20 TH-11-deoxycortisol/ 
  (TH-cortisone+6α-OH-TH-cortisone) 
THS/(THE+6OH-THE) Caulfield et al. 2002 (33) 
Kamrath et al. 2016 (31) 
21 TH-11-deoxycortisol/(TH-cortisone+ 
  6α-OH-TH-cortisone+6α-OH-β-cortolone) 
THS/(THE+6OH-THE+6OH-β-Cl) Caulfield et al. 2002, (33) 
Kamrath et al. 2016 (31) 
17α-HYDROXYLASE DEFICIENCY (17OHD) 
22 (11-dehydro-TH-corticosterone+TH-corticosterone+ 
  allo-TH-corticosterone)/TH-cortisone 
THA+THB+5αTHB/THE Krone et al. 2010 (34) 
Kamrath et al. 2016 (31) 
23 (11-dehydro-TH-corticosterone+TH-corticosterone+ 
  allo-TH-corticosterone)/6α-OH-TH-cortisone 
THA+THB+5αTHB/6OH-THE Krone et al. 2010 (34) 
Kamrath et al. 2016 (31) 
24 (11-dehydro-TH-corticosterone+ 
  TH-corticosterone+allo-TH-corticosterone)/ 
  (TH-cortisone+6α-OH-TH-cortisone) 
THA+THB+5αTHB/(THE+6OH-THE) Krone et al. 2010 (34) 
Kamrath et al. 2016 (31) 
25 (11-dehydro-TH-corticosterone+TH-corticosterone+ 
  allo-TH-corticosterone)/(TH-cortisone+ 
  6α-OH-TH-cortisone+6α-OH-β-cortolone) 
THA+THB+5αTHB/ 
  (THE+6OH-THE+6OH-β-Cl) 
Krone et al. 2010 (34) 
Kamrath et al. 2016 (31) 
26 (11-dehydro-TH-corticosterone+ 
  TH-corticosterone+allo-TH-corticosterone)/ 
  (androsterone+etiocholanolone) 
(THA+THB+5αTHB)/(AT+ET) Krone et al. 2010 (34) 
P450 OXIDOREDUCTASE DEFICIENCY (PORD) 
27 (17-OH-pregnanolone+pregnanetriol)/ 
  (androsterone+etiocholanolone) 
(17HP+PT)/(AT+ET) Krone et al. 2010 (34) 
28 (17-OH-pregnanolone+pregnanetriol)/TH-cortisone (17HP+PT)/THE Krone et al. 2010 (34) 
Kamrath et al. 2016 (31) 
29 (17-OH-pregnanolone+pregnanetriol)/ 
  6α-OH-TH-cortisone 
(17HP+PT)/6OH-THE Krone et al. 2010 (34) 
Kamrath et al. 2016 (31) 
30 (17-OH-pregnanolone+pregnanetriol)/ 
  (TH-cortisone+6α-OH-TH-cortisone) 
(17HP+PT)/(THE+6OH-THE) Krone et al. 2010 (34) 
Kamrath et al. 2016 (31) 
31 (17-OH-pregnanolone+pregnanetriol)/ 
  (TH-cortisone+6α-OH-TH-cortisone+ 
  6α-OH-β-cortolone) 
(17HP+PT)/ 
  (THE+6OH-THE+6OH-β-Cl) 
Krone et al. 2010 (34) 
Kamrath et al. 2016 (31) 
32 pregnanediol/TH-cortisone PD/THE Krone et al. 2010 (34) 
Kamrath et al. 2016 (31) 
33 pregnanediol/6α-OH-TH-cortisone PD/6OH-THE Krone et al. 2010 (34) 
Kamrath et al. 2016 (31) 
Table2
34 pregnanediol/(TH-cortisone+6α-OH-TH-cortisone) PD/(THE+6OH-THE) Krone et al. 2010, (34) 
Kamrath et al. 2016 (31) 
35 pregnanediol/(TH-cortisone+6α-OH-TH-cortisone+ 
  6α-OH-β-cortolone) 
PD/(THE+6OH-THE+6OH-β-Cl) Krone et al. 2010, (34) 
Kamrath et al. 2016 (31) 
APPARENT MINERALOCORTICOID EXCESS (AME)/11β-HSD2 DEFICIENCY (11HSD2D)   
36 cortisol/cortisone F/E Krone et al. 2010 (34) 
37 (TH-cortisol+allo-TH-cortisol )/TH-cortisone (THF+5αTHF)/THE Krone et al. 2010 (34) 
38 (α-cortol+β-cortol)/(α-cortolone+β-cortolone) (α-C+β-C)/(α-Cl+β-Cl) Krone et al. 2010 (34) 
39 (α-cortol+β-cortol)/(α-cortolone+β-cortolone+ 
  6α-OH-α-cortolone+1β-OH-β-cortolone+ 
  6α-OH-β-cortolone) 
(α-C+β-C)/(α-Cl+β-Cl+6OH-α-Cl+ 
  1β-OH-β-Cl+6OH-β-Cl) 
Krone et al. 2010 (34) 
40 (cortisol+cortisone)/(TH-cortisol+allo-TH-cortisol+ 
  TH-cortisone) 
(F+E)/(THF+5αTHF+THE) Krone et al. 2010 (34) 
APPARENT CORTISONE REDUCTASE DEFICIENCY (ACRD)/HEXOSE-6-PHOSPHATE DEHYDROGENASE (H6PDH)/ 
CORTISONE REDUCTASE DEFICIENCY (CRD)/11β-HSD1 DEFICIENCY (11HSD1D) 
41 TH-cortisone/(TH-cortisol+allo-TH-cortisol ) THE/(THF+5αTHF) Krone et al. 2010 (34) 
42 (α-cortolone+β-cortolone)/(α-cortol+β-cortol) (α-Cl+β-Cl)/(α-C+β-C) Krone et al. 2010 (34) 
43 (α-cortolone+β-cortolone+6α-OH-α-cortolone+ 
  1β-OH-β-cortolone+6α-OH-β-cortolone)/ 
  (α-cortol+β-cortol) 
(α-Cl+β-Cl+6OH-α-Cl+1β-OH-β-Cl+ 
  6OH-β-Cl)/(α-C+β-C) 
Krone et al. 2010 (34) 
5α-REDUCTASE DEFICIENCY (5ARD) 
44 TH-cortisol/allo-TH-cortisol THF/5αTHF Krone et al. 2010 (34) 
45 TH-corticosterone/allo-TH-corticosterone THB/5αTHB Krone et al. 2010 (34) 
a
Glucocorticoid metabolites in some ratios indicated in the references were replaced by different combinations of fetal urinary 
glucocorticoid metabolites where appropriate by analogy with Kamrath et al. 2016 (31). 
 
Table 3. Specific urine steroid metabolite ratios at 13 time-points in the first year of life representing specific enzyme activities of the steroid metabolism. The highest ratio and the 97.5
th
 quantile in parenthesis are presented. Age and sex dependency of each steroid ratio were estimated by multivariable linear 
quantile mixed models and the respective results are indicated in the columns “Age” and “Sex”. 
ID Steroid metabolite ratios   Week 1 Week 3 Week 5 Week 7 Week 9 Week 11 Week 13 Week 17 Week 21 Week 25 Week 33 Week 41 Week 49 Age Sex 
21-HYDROXYLASE DEFICIENCY (21OHD) 
  5 PTO/THE   0.0279 (0.0235) 0.062 (0.0434) 0.0478 (0.0468) 0.0369 (0.028) 0.04 (0.0201) 0.0639 (0.0264) 0.1198 (0.0954) 0.0293 (0.0154) 0.0227 (0.0167) 0.0862 (0.0508) 0.0475 (0.0364) 0.5318 (0.2335) 0.0987 (0.0928) no no 
  6 PTO/6OH-THE boys 0.0047 (0.0044) 0.0145 (0.0107) 0.006 (0.0053) 0.0043 (0.0043) 0.0058 (0.0049) 0.0066 (0.0061) 0.0096 (0.0078) 0.0107 (0.0095) 0.009 (0.0086) 0.017 (0.0149) 0.0195 (0.0189) 0.0208 (0.019) 0.1153 (0.1002) yes yes 
girls 0.0056 (0.0052) 0.0035 (0.0035) 0.0057 (0.005) 0.006 (0.0057) 0.005 (0.005) 0.0261 (0.0175) 0.0705 (0.041) 0.0076 (0.0074) 0.0155 (0.0134) 0.0285 (0.0251) 0.0488 (0.0392) 0.057 (0.0406) 0.0282 (0.0267) 
  7 PTO/(THE+6OH-THE) boys 0.0035 (0.0034) 0.0107 (0.0084) 0.0037 (0.0037) 0.0039 (0.0036) 0.0036 (0.0031) 0.0039 (0.0038) 0.0089 (0.007) 0.0078 (0.0065) 0.0045 (0.0045) 0.0066 (0.0065) 0.012 (0.0109) 0.008 (0.0075) 0.0532 (0.0457) no yes 
girls 0.0043 (0.0042) 0.0033 (0.0029) 0.0039 (0.0036) 0.0045 (0.0039) 0.0036 (0.0036) 0.0185 (0.0123) 0.0402 (0.0245) 0.0046 (0.0045) 0.0092 (0.0077) 0.012 (0.0118) 0.0241 (0.018) 0.0515 (0.0351) 0.0175 (0.017) 
  8 PTO/(THE+6OH-THE+6OH-β-Cl) boys 0.0022 (0.0021) 0.0088 (0.0067) 0.0033 (0.0031) 0.0028 (0.0027) 0.0028 (0.0025) 0.0034 (0.0033) 0.0071 (0.0058) 0.0074 (0.0062) 0.0044 (0.0043) 0.0063 (0.0063) 0.0116 (0.0104) 0.0079 (0.0074) 0.0464 (0.04) no yes 
girls 0.0032 (0.0028) 0.0024 (0.0022) 0.0034 (0.0029) 0.0037 (0.0033) 0.0032 (0.0031) 0.0103 (0.0074) 0.0382 (0.0228) 0.0041 (0.004) 0.0086 (0.0072) 0.0116 (0.0115) 0.0233 (0.0175) 0.047 (0.032) 0.0169 (0.0163) 
3β-HSD DEFICIENCY (3HSDD) 
  9 5PT/THE   1.88 (1.786) 1.467 (0.5684) 1.498 (1.411) 0.8546 (0.7751) 0.8008 (0.5927) 0.9749 (0.3978) 0.5489 (0.3453) 0.3163 (0.1815) 0.3809 (0.3244) 0.9418 (0.428) 0.922 (0.3987) 0.3437 (0.2133) 0.5945 (0.3575) no no 
10 5PT/6OH-THE   0.36 (0.304) 0.107 (0.0846) 0.13 (0.0967) 0.1575 (0.1228) 0.3249 (0.1673) 0.398 (0.1711) 0.175 (0.11) 0.169 (0.1233) 0.1847 (0.1392) 0.1325 (0.0974) 0.3785 (0.2132) 0.0881 (0.0872) 0.1116 (0.104) yes no 
11 5PT/(THE+6OH-THE)   0.3021 (0.2598) 0.0778 (0.0466) 0.1196 (0.0904) 0.1186 (0.1031) 0.2311 (0.1287) 0.2826 (0.1187) 0.1092 (0.0737) 0.1101 (0.0732) 0.1244 (0.0736) 0.1162 (0.0717) 0.2683 (0.1321) 0.0502 (0.0446) 0.0817 (0.0681) yes no 
12 5PT/(THE+6OH-THE+6OH-β-Cl)   0.2257 (0.2077) 0.0557 (0.0384) 0.0845 (0.0706) 0.0901 (0.078) 0.1732 (0.1021) 0.1566 (0.0836) 0.0907 (0.062) 0.0908 (0.0671) 0.1031 (0.0669) 0.0921 (0.0621) 0.2127 (0.1107) 0.0465 (0.0406) 0.0735 (0.0606) yes no 
13 DHEA/THE   0.4194 (0.3393) 0.2101 (0.1852) 1.153 (0.6294) 0.2533 (0.2077) 0.2023 (0.1993) 0.0969 (0.0732) 0.3599 (0.1114) 0.062 (0.0476) 0.0637 (0.0499) 0.4753 (0.2553) 0.0887 (0.0485) 0.0899 (0.0476) 0.08 (0.0594) no no 
14 DHEA/6OH-THE   0.0976 (0.081) 0.0466 (0.031) 0.0384 (0.034) 0.0373 (0.0314) 0.1024 (0.0545) 0.04 (0.0308) 0.2713 (0.0659) 0.0282 (0.0259) 0.0589 (0.039) 0.0669 (0.0521) 0.0713 (0.0563) 0.0322 (0.028) 0.0935 (0.0598) yes no 
15 DHEA/(THE+6OH-THE) boys 0.0737 (0.0503) 0.017 (0.0156) 0.0353 (0.0277) 0.0267 (0.0202) 0.0051 (0.0049) 0.0145 (0.0125) 0.0105 (0.0098) 0.0066 (0.0066) 0.0096 (0.0086) 0.0068 (0.0068) 0.0395 (0.0309) 0.0039 (0.0036) 0.0431 (0.0368) no yes 
girls 0.0626 (0.056) 0.0382 (0.0305) 0.0297 (0.0237) 0.024 (0.0228) 0.0654 (0.0533) 0.0244 (0.0225) 0.1547 (0.0918) 0.0179 (0.0176) 0.0306 (0.0255) 0.0586 (0.0454) 0.0133 (0.0126) 0.0109 (0.0102) 0.0066 (0.0063) 
16 DHEA/(THE+   
  6OH-THE+6OH-β-Cl) 
boys 0.0345 (0.0247) 0.0123 (0.0118) 0.0249 (0.0199) 0.0173 (0.0137) 0.0042 (0.0041) 0.0126 (0.0107) 0.0087 (0.0083) 0.0062 (0.0061) 0.0087 (0.0078) 0.0064 (0.0063) 0.0387 (0.0302) 0.0036 (0.0034) 0.0376 (0.0322) no yes 
girls 0.0379 (0.0304) 0.027 (0.0227) 0.0224 (0.0178) 0.0177 (0.0175) 0.0531 (0.0437) 0.0214 (0.0184) 0.1471 (0.0862) 0.0171 (0.016) 0.0277 (0.0236) 0.0465 (0.0362) 0.0126 (0.012) 0.0107 (0.01) 0.0063 (0.006) 
RATIO TO DISTINGUISH 3β-HSD DEFICIENCY FROM 21-HYDROXYLASE DEFICIENCY 
17 5PT/PTO   405.4 (106.4) 203 (49.89) 82.18 (41.31) 77.77 (72) 88.23 (66.22) 41.86 (37.58) 33.15 (30.27) 76.52 (44.36) 47.08 (37.43) 26.51 (23.62) 69.24 (35.44) 18.09 (17.92) 12 (11.8) yes no 
11β-HYDROXYLASE DEFICIENCY (11OHD) 
18 THS/THE   0.1391 (0.1241) 0.0926 (0.0887) 0.1087 (0.1075) 0.0339 (0.0306) 0.0306 (0.0223) 0.0341 (0.025) 0.104 (0.0553) 0.048 (0.0375) 0.0757 (0.0613) 0.227 (0.0969) 0.0663 (0.0657) 0.0783 (0.0676) 0.1084 (0.102) yes no 
19 THS/6OH-THE   0.0452 (0.0268) 0.0238 (0.02) 0.029 (0.0174) 0.0123 (0.0114) 0.0131 (0.0121) 0.0176 (0.0163) 0.0784 (0.0324) 0.0364 (0.0314) 0.0657 (0.0554) 0.0658 (0.061) 0.0833 (0.0792) 0.0817 (0.0734) 0.1283 (0.1071) yes no 
20 THS/(THE+6OH-THE)   0.0341 (0.0211) 0.0187 (0.016) 0.0126 (0.0101) 0.0067 (0.0064) 0.0073 (0.0073) 0.0101 (0.0087) 0.0447 (0.0175) 0.0184 (0.0175) 0.0306 (0.0297) 0.0277 (0.0276) 0.0318 (0.0283) 0.0316 (0.0301) 0.0449 (0.0413) yes no 
21 THS/(THE+6OH-THE+6OH-β-Cl)   0.016 (0.0144) 0.0135 (0.0102) 0.011 (0.0084) 0.0062 (0.0058) 0.0068 (0.0067) 0.0092 (0.0081) 0.0425 (0.0164) 0.0172 (0.0164) 0.0286 (0.0286) 0.0268 (0.0231) 0.0309 (0.0276) 0.0311 (0.029) 0.0441 (0.0399) yes no 
17α-HYDROXYLASE DEFICIENCY (17OHD) 
22 THA+THB+5αTHB/THE   1.592 (1.16) 0.814 (0.8001) 1.608 (0.9328) 1.172 (0.6845) 1.261 (0.7656) 0.7127 (0.596) 0.6943 (0.6644) 1.126 (0.6883) 1.133 (0.8644) 1.2 (1.155) 1.311 (1.178) 1.054 (0.9273) 1.208 (1.093) yes no 
23 THA+THB+5αTHB/6OH-THE   0.5168 (0.3189) 0.1942 (0.19) 0.2094 (0.1765) 0.2195 (0.2131) 0.5646 (0.4292) 0.467 (0.3029) 0.4984 (0.387) 0.5595 (0.334) 0.7406 (0.5888) 1.05 (0.7068) 1.287 (1.19) 1.396 (1.134) 1.898 (1.578) yes no 
24 THA+THB+5αTHB/(THE+6OH-THE)   0.3901 (0.2378) 0.1551 (0.1489) 0.1645 (0.1521) 0.179 (0.15) 0.39 (0.2779) 0.2821 (0.1909) 0.2842 (0.231) 0.3738 (0.2172) 0.3815 (0.3336) 0.5201 (0.3898) 0.6497 (0.5141) 0.5179 (0.4412) 0.7382 (0.6438) yes no 
25 THA+THB+5αTHB/ 
  (THE+6OH-THE+6OH-β-Cl) 
  0.1827 (0.1431) 0.1185 (0.1063) 0.1377 (0.1182) 0.1231 (0.1084) 0.3328 (0.2276) 0.2535 (0.1668) 0.2702 (0.2049) 0.3239 (0.1964) 0.3618 (0.3197) 0.4892 (0.3666) 0.6175 (0.4943) 0.4959 (0.4219) 0.7103 (0.6157) yes no 
26 (THA+THB+5αTHB)/(AT+ET) boys 47.83 (41.6) 22.25 (18.03) 46 (37.95) 19.26 (17.85) 34.34 (25.92) 22.51 (20.89) 23.8 (21.28) 26.25 (26.04) 38.17 (38.15) 65.24 (60.86) 60.72 (56.8) 103.9 (96.52) 131.3 (119.2) yes yes 
girls 18.99 (17.16) 26.23 (25.11) 26.62 (24.91) 37.15 (34.29) 119.8 (75.38) 68.22 (62.45) 96.02 (89.17) 67.67 (54.33) 93.58 (78.06) 123.6 (92.43) 52.84 (48.68) 52.71 (43.24) 119.4 (95.83) 
P450 OXIDOREDUCTASE DEFICIENCY (PORD) 
27 (17HP+PT)/(AT+ET)   3.995 (3.6) 5.826 (5.012) 4.228 (3.89) 3.086 (3.081) 6.044 (5.146) 5.2 (4.196) 4.528 (3.847) 6.938 (5.868) 7.227 (7.094) 6.678 (6.376) 7.536 (6.717) 5.363 (4.387) 6.62 (5.56) yes no 
28 (17HP+PT)/THE   0.305 (0.2503) 0.8103 (0.3641) 0.4091 (0.3638) 0.3157 (0.2919) 0.276 (0.1115) 0.2231 (0.1879) 0.5293 (0.5015) 0.342 (0.2918) 0.2763 (0.2308) 0.3979 (0.3963) 0.3015 (0.2118) 0.8954 (0.4857) 0.7659 (0.6574) yes no 
29 (17HP+PT)/6OH-THE   0.0787 (0.037) 0.0788 (0.0544) 0.0508 (0.0437) 0.0407 (0.0384) 0.065 (0.0412) 0.0911 (0.0862) 0.3764 (0.1391) 0.1574 (0.1317) 0.1882 (0.1496) 0.1821 (0.1522) 0.2658 (0.2102) 0.152 (0.1446) 0.3632 (0.2785) yes no 
30 (17HP+PT)/(THE+6OH-THE)   0.0594 (0.0317) 0.0537 (0.0492) 0.0339 (0.0331) 0.0313 (0.0248) 0.0526 (0.0277) 0.0647 (0.0546) 0.2146 (0.0946) 0.1006 (0.0933) 0.112 (0.0842) 0.079 (0.077) 0.0831 (0.0814) 0.0867 (0.0825) 0.1675 (0.1516) yes no 
31 (17HP+PT)/ 
  (THE+6OH-THE+6OH-β-Cl) 
  0.0278 (0.0178) 0.0414 (0.0371) 0.0266 (0.0256) 0.0254 (0.0205) 0.0441 (0.0227) 0.0453 (0.038) 0.2041 (0.0832) 0.0874 (0.0863) 0.1043 (0.0803) 0.0743 (0.0734) 0.0785 (0.0774) 0.0792 (0.0759) 0.146 (0.1363) yes no 
32 PD/THE   0.3413 (0.2859) 0.1726 (0.1251) 0.2996 (0.146) 0.0787 (0.054) 0.1221 (0.1171) 0.0425 (0.0342) 0.7094 (0.4788) 0.1661 (0.0676) 0.1036 (0.0937) 0.1208 (0.1106) 0.0521 (0.0456) 0.0616 (0.0515) 0.1044 (0.1034) no no 
33 PD/6OH-THE   0.0489 (0.0375) 0.0336 (0.0181) 0.0342 (0.0237) 0.008 (0.0078) 0.0556 (0.0539) 0.0171 (0.0165) 0.3912 (0.3535) 0.1065 (0.0527) 0.0709 (0.0619) 0.1044 (0.0624) 0.0514 (0.0421) 0.0641 (0.0503) 0.0503 (0.0427) yes no 
34 PD/(THE+6OH-THE)   0.0428 (0.0332) 0.0262 (0.0146) 0.0228 (0.017) 0.0063 (0.0059) 0.0377 (0.0347) 0.0122 (0.0105) 0.2521 (0.2059) 0.0649 (0.0286) 0.0421 (0.0305) 0.0414 (0.029) 0.0227 (0.0219) 0.0217 (0.0186) 0.0251 (0.021) yes no 
Table3
35 PD/(THE+6OH-THE+6OH-β-Cl)   0.0354 (0.0173) 0.021 (0.0107) 0.017 (0.0132) 0.0052 (0.0049) 0.0338 (0.0286) 0.0111 (0.0093) 0.2325 (0.1947) 0.055 (0.0254) 0.0405 (0.0296) 0.0399 (0.0279) 0.0223 (0.0213) 0.0213 (0.018) 0.0237 (0.0201) yes no 
APPARENT MINERALOCORTICOIDEXCESS (AME)/11β-HSD2 DEFICIENCY (11HSD2D) 
36 F/E   76.61 (54.97) 38.95 (13.99) 10.19 (4.742) 14.66 (3.681) 28.3 (3.242) 35.22 (6.76) 51.993 (18.713) 16.349 (6.801) 1.681 (1.555) 11.061 (5.317) 3.019 (2.689) 20.805 (10.094) 4.239 (3.869) yes no 
37 (THF+5αTHF)/THE   0.27 (0.078) 0.2815 (0.1126) 0.2269 (0.1987) 0.2513 (0.213) 0.4203 (0.3314) 0.798 (0.6696) 1.356 (1.269) 2.105 (1.904) 2.162 (1.632) 3.614 (3.455) 4.331 (2.878) 2.609 (2.459) 4.999 (4.166) yes no 
38 (α-C+β-C)/(α-Cl+β-Cl)   2.746 (1.323) 1.1 (0.7428) 2.408 (1.493) 0.9456 (0.941) 1.232 (1.009) 0.5002 (0.4655) 0.8667 (0.8622) 0.8523 (0.7477) 0.6627 (0.5625) 0.8173 (0.7338) 1.424 (1.085) 0.6541 (0.6397) 0.8764 (0.8314) yes no 
39 (α-C+β-C)/(α-Cl+β-Cl+6OH-α-Cl+ 
  1β-OH-β-Cl+6OH-β-Cl) 
  0.0542 (0.0362) 0.0391 (0.0275) 0.0677 (0.0488) 0.0598 (0.0586) 0.0808 (0.0414) 0.0507 (0.0358) 0.2061 (0.1114) 0.075 (0.0522) 0.0726 (0.0553) 0.0524 (0.0497) 0.1359 (0.105) 0.0715 (0.0684) 0.1059 (0.0988) yes no 
40 (F+E)/(THF+5αTHF+THE)   0.8312 (0.8188) 0.4776 (0.4274) 1.032 (0.8279) 1.051 (0.6255) 1.033 (0.4796) 0.3264 (0.2954) 0.5463 (0.4871) 0.2268 (0.2013) 0.3098 (0.2645) 0.4643 (0.3087) 0.5877 (0.2672) 0.1251 (0.1024) 0.1288 (0.1262) yes no 
APPARENT CORTISONE REDUCTASE DEFICIENCY (ACRD)/HEXOSE-6-PHOSPHATE DEHYDROGENASE (H6PDH)/ 
CORTISONE REDUCTASE DEFICIENCY (CRD)/11β-HSD1 DEFICIENCY (11HSD1D) 
41 THE/(THF+5αTHF)   128.7 (118.4) 108.2 (101.9) 92.34 (80.94) 65.76 (40.87) 48.39 (41.2) 23.37 (21.85) 19.13 (16.02) 6.33 (6.266) 5.69 (3.828) 35.866 (10.195) 12.04 (5.853) 1.452 (1.418) 1.393 (1.374) yes no 
42 (α-Cl+β-Cl)/(α-C+β-C)   14.54 (13.19) 18.99 (14.15) 10.79 (9.641) 18.04 (12.58) 14.92 (14.5) 15.29 (11.95) 14.65 (13.92) 19.28 (13.88) 9.57 (8.913) 10.61 (8.578) 5.223 (4.688) 5.088 (4.922) 4.44 (4.047) yes no 
43 (α-Cl+β-Cl+6OH-α-Cl+1β-OH-β-Cl+ 
  6OH-β-Cl)/(α-C+β-C) 
  617.3 (468.2) 433.5 (301.7) 260.4 (231.5) 295.6 (219.7) 313.6 (280.9) 231.7 (175.9) 258.4 (241.5) 273 (179.7) 117.7 (116.1) 149 (139.4) 143.7 (103.5) 82.23 (75.44) 49.12 (48.34) yes no 
5α-REDUCTASE DEFICIENCY (5ARD) 
44 THF/5αTHF boys 4.164 (3.872) 3.094 (2.774) 1.093 (1.008) 0.4993 (0.4883) 0.5926 (0.5842) 0.508 (0.4299) 0.4859 (0.405) 0.4421 (0.4147) 0.384 (0.3722) 0.5647 (0.5486) 0.895 (0.7668) 0.4919 (0.4781) 0.6935 (0.6768) yes yes 
girls 3.285 (2.933) 3.831 (3.561) 4.385 (4.03) 0.9944 (0.9245) 0.6356 (0.5879) 0.567 (0.518) 0.9602 (0.7674) 0.3931 (0.3772) 0.4925 (0.474) 1.069 (0.9217) 0.4492 (0.4481) 1.084 (0.8839) 1.778 (1.53) 
45 THB/5αTHB boys 222.2 (137.9) 26.28 (19.46) 8.744 (8.38) 61.89 (47.37) 95.86 (91.44) 202 (155) 105.7 (99.16) 480.9 (432.8) 131.9 (129.5) 207.5 (207.4) 193.9 (186.1) 307.9 (282.5) 136.9 (136.5) yes yes 
girls 152.5 (137.9) 34.75 (23.85) 60.63 (38.52) 15.1 (14.89) 103.9 (86.98) 82.07 (80.31) 142.9 (126) 202 (185.5) 327.6 (304.5) 246.2 (192.5) 263.8 (260.8) 169.4 (161) 147.2 (137) 
Number of calculated ratios per week: week 1: 34-36; week 3: 36-38; week 5: 32-35; week 7: 32-35; week 9: 36-38; week 11: 31-35; week 13: 34-38; week 17: 32-33; week 21: 30-32; week 25: 30-32; week 33: 26-28; week 41: 21-24; week 49: 19-20. 
 
